Background: The inclusion of HER2 ultra-low in the DESTINY
Breast 06 clinical trial further complicates the detection of HER2,
posing challenges for accurate assessment. This study employed
formalin-fixed paraffin-embedded (FFPE) blocks derived from
tumor samples to evaluate their impact on breast cancer cases
exhibiting either HER2 no staining (HER2-null) or HER2 ultra-low,
under real-world conditions.
第一作者机构：[1]Hebei Med Univ, Dept Pathol, Hosp 4, Shijiazhuang, Peoples R China
推荐引用方式(GB/T 7714)：
Li Jinze,Liu Hongbo,Ding Yan,et al.Can HER2 Ultra-low with Tumor FFPE Blocks Impact on The Accurate Diagnosis of HER2 in Breast Cancer?[J].LABORATORY INVESTIGATION.2025,105(3):doi:10.1016/j.labinv.2024.102414.
APA：
Li, Jinze,Liu, Hongbo,Ding, Yan,Wu, Si,Shang, Jiuyan&Liu, Yueping.(2025).Can HER2 Ultra-low with Tumor FFPE Blocks Impact on The Accurate Diagnosis of HER2 in Breast Cancer?.LABORATORY INVESTIGATION,105,(3)
MLA：
Li, Jinze,et al."Can HER2 Ultra-low with Tumor FFPE Blocks Impact on The Accurate Diagnosis of HER2 in Breast Cancer?".LABORATORY INVESTIGATION 105..3(2025)
